Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome
JACC: Clinical Electrophysiology · 2024-02 · 10 (2) · 346-355
DOI: 10.1016/j.jacep.2023.10.015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2024-02. Verfasst von Stavros Stavrakis und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: stavros-stavrakis@ouhsc.edu. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Postural Orthostatic Tachycardia Syndrome. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIMHD NIH HHS, NIH.
Abstract (Originalsprache)
BACKGROUND: Low-level transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus is antiarrhythmic and anti-inflammatory in animals and humans. Preliminary studies show that transcutaneous vagus nerve stimulation (tVNS) is beneficial in animal models of postural tachycardia syndrome (POTS). OBJECTIVES: In this study the authors conducted a sham-controlled, double-blind, randomized clinical trial to examine the effect of tVNS on POTS over a 2-month period relative to sham stimulation. METHODS: tVNS (20 Hz, 1 mA below discomfort threshold) was delivered using an ear clip attached to either the tragus (active; n = 12) or the ear lobe (sham; n = 14) for 1 hour daily over a 2-month period. Postural tachycardia was assessed during the baseline and 2-month visit. Heart rate variability based on 5-minute electrocardiogram, serum cytokines, and antiautonomic autoantibodies were measured at the respective time points. RESULTS: Mean age was 34 ± 11 years (100% female; 81% Caucasian). Adherence to daily stimulation was 83% in the active arm and 86% in the sham arm (P > 0.05). Postural tachycardia was significantly less in the active arm compared with the sham arm at 2 months (mean postural increase in heart rate 17.6 ± 9.9 beats/min vs 31.7 ± 14.4 beats/min; P = 0.01). Antiadrenergic autoantibodies and inflammatory cytokines were lower in the active arm compared with the sham arm at 2 months (P < 0.05). Heart rate variability was better in the active arm. No device-related side effects were observed. CONCLUSIONS: Our results support the emerging paradigm of noninvasive neuromodulation to treat POTS. Mechanistically, this effect appears to be related to reduction of antiautonomic autoantibodies and inflammatory cytokines, and improvement in autonomic tone. Further studies are warranted. (Autoimmune Basis for Postural Tachycardia Syndrome; NCT05043051).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: stavros-stavrakis@ouhsc.edu.
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Förderung
- NHLBI NIH HHS
- NIMHD NIH HHS
- NIH
Zitieren
APA
Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Abideen Asad, Z. U., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome. JACC: Clinical Electrophysiology, 10(2), 346-355. https://doi.org/10.1016/j.jacep.2023.10.015
Vancouver
Stavrakis S, Chakraborty P, Farhat K, Whyte S, Morris L, Abideen Asad ZU, et al. Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome. JACC: Clinical Electrophysiology. 2024;10(2):346-355. doi:10.1016/j.jacep.2023.10.015
BibTeX
@article{Stavrakis2024,
author = {Stavrakis, Stavros and Chakraborty, Praloy and Farhat, Kassem and Whyte, Seabrook and Morris, Lynsie and Abideen Asad, Zain Ul and Karfonta, Brittany and Anjum, Juvaria and Matlock, H Greg and Cai, Xue and Yu, Xichun},
title = {Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome},
journal = {JACC: Clinical Electrophysiology},
year = {2024},
volume = {10},
number = {2},
pages = {346--355},
doi = {10.1016/j.jacep.2023.10.015}
}
EUVIMED